We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Epistem Awarded Further Long Term Funding for NIH Biodefence Programme

Listen with
Speechify
0:00
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: 1 minute

In the first subcontract commencing in 2006, Epistem received approximately 3.5 million USD to develop models and evaluate novel drugs that can treat the effects of radiation damage to the gastrointestinal tract. The new five year subcontract is expected to extend and grow the scope of the collaborative relationship.

This UMSOM programme, referred to as the Medical Countermeasures against Radiological Threats (MCART) programme, is funded by the NIH's National Institute of Allergy and Infectious Diseases (NIAID), and aims to identify and develop new treatments for use in the event of a radiological or nuclear incident. As a subcontractor, Epistem is a member of the research consortium which has been awarded the contract and comprises radiobiology experts, each with specialist knowledge of the effects of radiation in different tissues of the body. Epistem's role is to provide specialized gastrointestinal models to assess the efficacy and mode of action of new drugs entering the programme. In the previous subcontract, the Company refined drug screening methods, further characterised the biology of radiation damage in the gastrointestinal tract and assessed several new drug candidates. Other members of the consortium, which is led by the UMSOM, include Indiana University School of Medicine and Duke University in the USA. Epistem is the only research facility outside of North America within the consortium.

Dr Catherine Booth, Managing Director and Co-Founder of Epistem commented, "The past few years collaboration with NIAID and the UMSOM have been incredibly successful. A series of models have been developed and used to screen potential treatments for acute radiation damage. This fresh contract covering five years will allow us to progress successful candidate drugs, in addition to developing models to assess treatments for the delayed effect of radiation damage".

Professor Tom MacVittie, Ph.D., Principal Investigator and MCART Director at the UMSOM said "I am extremely proud to head this consortium. We have assembled a group of world experts in the field of radiation damage. This new award validates the hard work and progress made from this collaboration over the previous five years. We are hopeful that the outcome from the next five years will be the successful identification and evaluation of radiation mitigators that will become available to the strategic national stockpile"